somatotroph raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-13 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
The compressional wave solutions used in the electromagnetic cloaking are transferred to material fluidic solutions where fluid motion is parallel to the wavevector. The computations then show that coordinate transformations can be applied to acoustic media when restricted to normal incidence in two dimensions. Next, the electromagnetic cloaking shell is referenced as an exact equivalence for a simulated demonstration of the acoustic cloaking shell. Bulk modulus and mass density determine the spatial dimensions of the cloak, which can bend any incident wave around the center of the shell. In a simulation with perfect conditions, because it is easier to demonstrate the principles involved, there is zero scattering in any direction.
Dysfunctional structure of one particular laminin, laminin-211, is the cause of one form of congenital muscular dystrophy. Laminin-211 is composed of α2, β1, and γ1 chains. This laminin's distribution includes the brain and muscle fibers. In muscle, it binds to alpha-dystroglycan and integrin alpha7—beta1 via the G domain, and via the other end, it binds to the extracellular matrix. Abnormal laminin-332, essential for epithelial cell adhesion to the basement membrane, leads to junctional epidermolysis bullosa, characterized by generalized blisters, exuberant granulation tissue of the skin and mucosa, and pitted teeth. Malfunctional laminin-521 in the kidney filter causes leakage of protein into the urine and nephrotic syndrome.
=== Electrolyte replacement === Potassium replacement is often required as the metabolic problems are corrected. It is generally replaced at a rate of 10 mEq per hour as long as there is adequate urinary output.
=== Acute Metabolic Decompensation === When Leucine plasma levels elevate due to not following the strict MSUD diets, infection, or physiological stress this may induce acute metabolic decompensation. Individuals with lower residual BCKAD activity have increased risk. Typically Leucine levels >380 mmol/L will lead to metabolic decompensation. The goal in treating acute decompensation is to stop protein breakdown and increase protein synthesis. When an individual is facing acute metabolic decompensation it is important to remove or correct the stressor that is causing physiologic decompensation. During decompensation, the individual must be still receiving the proper amount of calories, insulin, free amino acids, isoleucine, and valine to help promote protein synthesis.
Sources: en.wikipedia.org
== History == Twinlab was founded by David and Jean Blechman in 1968 and run by them and their sons – Neil, Brian, Ross, Steve and Dean. Using experience gained from over 20 years as a pharmaceutical salesman, David Blechman named the company for his two sets of twins and started marketing a liquid protein supplement from their family garage. Sales of Twinlab's only product skyrocketed in the 1970s, in part from the success of a 1976 book entitled The Last Chance Diet — When Everything Else Has Failed: Dr. Linn's Protein-Sparing Fast Program. Dr. Robert Linn was a Pennsylvania osteopath, who had begun prescribing for his overweight patients a program of fasting and four- to six-ounce daily doses of liquid protein. His book sold extremely well, and Dr. Linn's diet became the latest weight-loss fad diet. This led to increased sales for Twinlab's liquid protein. As with many fad diets, the fasting/liquid protein craze came to a halt when in late 1976 and early 1977 there were reports of the deaths of 58 people who had followed Linn's diet. Following a U.S. Food and Drug Administration (FDA) investigation the associated coverage of the popular diet and its potential side effects by Newsweek, Parents' Magazine, and Science Digest, the liquid protein market bottomed out, and Twinlab's revenues declined sharply forcing the company to cut nearly all of its 150-person workforce. In the 1980s Twinlab branched out formulating new vitamin and nutritional supplements and purchased a publishing company called Advanced Research Press, Inc.
Lloyd George and Balfour remained in government until the collapse of the coalition in October 1922. Under the new Conservative government, attempts were made to identify the background to and motivations for the declaration. A private Cabinet memorandum was produced in January 1923, providing a summary of the then-known Foreign Office and War Cabinet records leading up to the declaration. An accompanying Foreign Office note asserted that the primary authors of the declaration were Balfour, Sykes, Weizmann, and Sokolow, with "perhaps Lord Rothschild as a figure in the background", and that "negotiations seem to have been mainly oral and by means of private notes and memoranda of which only the scantiest records seem to be available." Following the 1936 general strike that was to degenerate into the 1936–1939 Arab revolt in Palestine, the most significant outbreak of violence since the Mandate began, a British Royal Commission – a high-profile public inquiry – was appointed to investigate the causes of the unrest. The Palestine Royal Commission, appointed with significantly broader terms of reference than the previous British inquiries into Palestine, completed its 404-page report after six months of work in June 1937, publishing it a month later. The report began by describing the history of the problem, including a detailed summary of the origins of the Balfour Declaration. Much of this summary relied on Lloyd-George's personal testimony; Balfour had died in 1930 and Sykes in 1919. He told the commission that the declaration was made "due to propagandist reasons ...
51 articles on history of Chinese medicine; called "impressive and essential" for latest scholarship and trustworthy bibliographic sources. "(Review) H-Sci-Med-Tech, July 2023. McGrew, Roderick. Encyclopedia of Medical History (1985), brief history on pp. 56–59 Needham J (2000). Sivin N (ed.). Part VI: Medicine. Science and Civilisation in China. Vol. 6, Biology and Biological Technology. Cambridge University Press. ISBN 978-0-521-63262-1. OCLC 163502797. Palmer, James (13 June 2013), "Do Some Harm", Aeon Raphals, Lisa (Winter 2020), "Chinese Philosophy and Chinese Medicine", in Zalta, Edward N. (ed.), The Stanford Encyclopedia of Philosophy, Metaphysics Research Lab, Stanford University Shelton, Tamara Venit (2019). Herbs and Roots: A History of Chinese Doctors in the American Medical Marketplace. New Haven: Yale University Press. ISBN 978-0-300-24940-8. Unschuld, Paul (1986). Nan-Ching: The Classic of Difficult Issues. Berkeley: University of California Press. ISBN 978-0-520-05372-4. —— (1986a). Medicine in China: A History of Pharmaceutics. Berkeley: University of California Press. ISBN 978-0-520-05025-9. —— (2000). Medicine in China: Historical Artifacts and Images. Munich: Prestel. ISBN 978-3-7913-2149-3. —— (2018). Traditional Chinese Medicine: Heritage and Adaptation [Traditionelle chinesische Medizin (2013)]. Translated by Bridie J. Andrews. New York: Columbia University Press. ISBN 978-0-231-17500-5.
{\displaystyle {\boldsymbol {\sigma }}={\begin{bmatrix}-p+{\cfrac {\mu J_{m}(1+\gamma ^{2})}{J_{m}-\gamma ^{2}}}&{\cfrac {\mu J_{m}\gamma }{J_{m}-\gamma ^{2}}}&0\\{\cfrac {\mu J_{m}\gamma }{J_{m}-\gamma ^{2}}}&-p+{\cfrac {\mu J_{m}}{J_{m}-\gamma ^{2}}}&0\\0&0&-p+{\cfrac {\mu J_{m}}{J_{m}-\gamma ^{2}}}\end{bmatrix}}}
== Treatment == There is no direct cure for Hypermobility Spectrum Disorder, but its symptoms can be treated. Physiotherapy, particularly exercise, is the main treatment for the condition, although there is only limited evidence for its effectiveness.
Sources: en.wikipedia.org
=== Organoeinsteinium compounds === Einsteinium's high radioactivity has a potential use in radiation therapy, and organometallic complexes have been synthesized in order to deliver einsteinium to an appropriate organ in the body. Experiments have been performed on injecting einsteinium citrate (as well as fermium compounds) to dogs. Einsteinium(III) was also incorporated into β-diketone chelate complexes, since analogous complexes with lanthanides previously showed strongest UV-excited luminescence among metallorganic compounds. When preparing einsteinium complexes, the Es3+ ions were 1000 times diluted with Gd3+ ions. This allowed reducing the radiation damage so that the compounds did not disintegrate during the 20 minutes required for the measurements. The resulting luminescence from Es3+ was much too weak to be detected. This was explained by the unfavorable relative energies of the individual constituents of the compound that hindered efficient energy transfer from the chelate matrix to Es3+ ions. Similar conclusion was drawn for americium, berkelium and fermium. Luminescence of Es3+ ions was however observed in inorganic hydrochloric acid solutions as well as in organic solution with di(2-ethylhexyl)orthophosphoric acid. It shows a broad peak at about 1064 nanometers (half-width about 100 nm) which can be resonantly excited by green light (ca. 495 nm wavelength). The luminescence has a lifetime of several microseconds and the quantum yield below 0.1%.
=== PCNA-PIDDosome === In addition to the signaling pathways previously discussed, PIDD1 is essential for translesion DNA synthesis (TLS), which allows for DNA extension across damaged regions in response to UV radiation. Within the nucleus, PIDD1 has been observed to associate with critical components of the replication machinery, such as proliferating cell nuclear antigen (PCNA) and replication factor C subunits RFC4 and RFC5, forming a complex referred to as the PCNA-PIDDosome. These proteins were identified as interacting partners of overexpressed PIDD1 through mass spectrometry analysis. PCNA functions as a DNA-sliding clamp that depends on replication factor C (RFC) for its correct positioning on DNA and is crucial for loading DNA polymerases during the replication process. Additionally, PCNA is essential for various DNA repair activities. Importantly, the interactions among [8PIDD]]1, PCNA, and RFC5 are facilitated by their ZU5 domains. As a result, this complex can only form with full-length PIDD1 or, due to the limited availability of full-length PIDD1 and the preferential nuclear localization of its primary autoprocessing product, with PIDD-C.
The purpose of the puncture is to restore a person's ability to speak after the vocal cords have been removed. Sometimes as an anatomical variation one or more of the tracheal rings are formed as complete rings, rather than horseshoe shaped rings. These O rings are smaller than the normal C-shaped rings and can cause narrowing (stenosis) of the trachea, resulting in breathing difficulties. An operation called a slide tracheoplasty can open up the rings and rejoin them as wider rings, shortening the length of the trachea. Slide tracheoplasty is said to be the best option in treating tracheal stenosis. Mounier-Kuhn syndrome is a rare congenital disorder of an abnormally enlarged trachea, characterised by absent elastic fibres, smooth muscle thinning, and a tendency to get recurrent respiratory tract infections.
Gene expression in mammals is regulated by many cis-regulatory elements, including core promoters and promoter-proximal elements that are located near the transcription start sites of genes, upstream on the DNA (towards the 5' region of the sense strand). Other important cis-regulatory modules are localized in DNA regions that are distant from the transcription start sites. These include enhancers, silencers, insulators and tethering elements. Enhancers and their associated transcription factors have a leading role in the regulation of gene expression. Enhancers are genome regions that regulate genes. Enhancers control cell-type-specific gene expression programs, most often by looping through long distances to come in physical proximity with the promoters of their target genes. Multiple enhancers, each often tens or hundred of thousands of nucleotides distant from their target genes, loop to their target gene promoters and coordinate with each other to control gene expression. The illustration shows an enhancer looping around to come into proximity with the promoter of a target gene. The loop is stabilized by a dimer of a connector protein (e.g. dimer of CTCF or YY1). One member of the dimer is anchored to its binding motif on the enhancer and the other member is anchored to its binding motif on the promoter (represented by the red zigzags in the illustration). Several cell function-specific transcription factors (among the about 1,600 transcription factors in a human cell) generally bind to specific motifs on an enhancer.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.